Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

BACKGROUND: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants born preterm or at full term against medically attended RSV lower respiratory tract infection (LRTI). In the MEDLE...

Descripción completa

Detalles Bibliográficos
Autores principales: Simões, Eric A F, Madhi, Shabir A, Muller, William J, Atanasova, Victoria, Bosheva, Miroslava, Cabañas, Fernando, Baca Cots, Manuel, Domachowske, Joseph B, Garcia-Garcia, Maria L, Grantina, Ineta, Nguyen, Kim A, Zar, Heather J, Berglind, Anna, Cummings, Celeste, Griffin, M Pamela, Takas, Therese, Yuan, Yuan, Wählby Hamrén, Ulrika, Leach, Amanda, Villafana, Tonya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940918/
https://www.ncbi.nlm.nih.gov/pubmed/36634694
http://dx.doi.org/10.1016/S2352-4642(22)00321-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940918/
https://www.ncbi.nlm.nih.gov/pubmed/36634694
http://dx.doi.org/10.1016/S2352-4642(22)00321-2

Ejemplares similares